Patient Home Monitoring (PHM) Releases First Quarter 2012 Overview in Advance of Investor Roadshow

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today released an overview of financial
highlights for the fiscal first quarter of 2012, ending December 2011 in advance
of an investor road show in New York and Montreal Jan 23-26.


FYQ1 2012 Highlights



--  Revenues in excess of $845,000 for the quarter. 
    --  Quarterly Growth: Up from $616,000 in the prior quarter, a 37%
        increase. 
    --  Annual Growth: Up from $134,000 in Q1 2011, a 530% increase over the
        same quarter in 2011.
--  19,434 INR tests(1) recorded in FYQ1 2012. 
    --  Quarterly Growth: Up from 15,194 in the prior quarter, a 28%
        increase over the last quarter. 
    --  Annual Growth: Up from 3,824 INR test recorded in Q1 2011, a 408%
        increase over the same quarter in 2011. 
    --  Current Growth Rate: For the last month in the quarter, December
        2011, PHM recorded 7,008 INR tests.
--  Shipped over 300 meters between November and December, historically slow
    months. 
--  Achieved quarterly gross margin of over 60% 
--  Generated positive Adjusted EBITDA before patient acquisition costs(2)
    (operating profit) to $220,000 up from $123,687 the prior quarter.



"We continue to have surging quarterly revenue growth with our annuity-based
revenue model." Said Dr. Jaime Gerber, CEO of PHM. "This is our fifth quarter of
commercial operations and it is exciting to compare this quarter, our fiscal
first quarter of 2012, to our fiscal first quarter of 2011 and see 530% growth
in revenue over just 12 months. I also think it is a tremendous accomplishment
to have operational profitability just 12 months after we started commercial
operations. 2012 promises to be another year of hyper growth for PHM.


PHM announced last quarter that is was seeking to secure $1,200,000 in
convertible debenture financing. The proceeds of the financing are being used to
purchase meters. Because PHM generated better than expected profits in the
fiscal first quarter, the company decided to end the offering early, issuing a
total of only $783,000.00. PHM anticipates it can secure traditional equipment
financing debt in the coming months to finance further meter purchased. Details
of each closing can be found on www.sedar.com. In connection with PHM's final
anticipated closing, PHM will have paid a total of $40,980 and issued 273,200
broker warrants with a $0.15 strike price expiring two years from the date of
grant. All securities issued pursuant to the financing will be subject to a
four-month hold period.


Complete financial results for the full fiscal year 2011 and the fiscal first
quarter 2012 will be available January 31, 2012 through a press release and
filings on Sedar. 


(1) International normalized ratio ("INR") tests and number of cardiology groups
with patients testing are used as measures of current and future sales
performance. Please refer to the "Non-GAAP Measures" section of PHM's MD&A for
further discussion on these operational measures.


(2) Operational Profitability is defined as Adjusted EBITDA before patient
acquisition costs. In calculating Adjusted EBITDA before patient acquisition
costs certain items are excluded from net loss including interest, taxes,
amortization, non-cash stock-based compensation and patient acquisition costs.
Please refer to the "Non-GAAP Measures" section of PHM's MD&A for further
discussion on these operational measures at http://phmhometesting.com/investor.


Reconciliation of Non-GAAP measures:



                                        Q4 FY 2011               Q1 FY 2012 
Adjusted EBITDA                      $  123,687.00            $  220,000.00 
Less: Amortization                   $   50,446.00            $   59,000.00 
Less: Stock Based Compensation       $   17,054.00            $   29,000.00 
Less: Patient Acquisition Costs      $  352,743.00            $  294,000.00 
----------------------------------------------------------------------------
Net Loss                             $ (296,556.00)           $ (162,000.00)



While the Q1 figures have not been finalized or released, PHM does not expect
any material adjustments.


About PHM

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(r) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value-added
service provider to expand into other home-based services for these patients and
their referring physicians.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.